0001213900-26-044165
SEC filingREMSleep deepened losses amid an 85.7% revenue collapse during its pivot from CPAP machines to DeltaWave commercialization, with operating losses expanding due to elevated expenses despite some cost reductions and positive initial customer reception.
Revenue plummeted 85.7% to $16.7K in FY 2025 from $117.2K in FY 2024, as REMSleep discontinued higher-volume CPAP machine sales to focus on commercializing its patented DeltaWave nasal pillow interfaces. This strategic shift aligns with FDA 510(k) expansion and critical Pricing, Data Analysis, and Coding (PDAC) approval for Medicare reimbursement across the entire product line, including new configurations and resupply SKUs. These milestones position DeltaWave for broader distribution through DME providers and hospitals, where reimbursement drives adoption. Initial customer reactions have been positive, with sales teams actively building a sales funnel amid typical 3-month onboarding cycles for durable medical equipment. Management expects sales to ramp in Q2 2026 as these efforts mature, though the 2025 topline reflects execution risks in a market led by ResMed and Philips, where transitioning from legacy products tests market traction.
Gross profit declined 77.7% to $4.0K from $18.0K, yet the gross margin remained stable at 24.0%, indicating consistent pricing power on the minimal DeltaWave volumes generated during launch. This resilience underscores the potential value of DeltaWave's differentiated design, even as scale remains elusive.
Cash from operations improved to -$502.8K used from -$683.1K, generating free cash flow of -$627.5K after $124.7K in stable capital expenditures. This moderation stems from targeted cost controls in professional services and facilities, providing modest breathing room. However, the Company's ability to secure future capital through equity or debt remains uncertain, emphasizing liquidity as a core risk while DeltaWave gains traction.